European Commission Approves Methylnaltrexone Bromide for Opioid-Induced Constipation in Advanced Illness
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




European Commission Approves Methylnaltrexone Bromide for Opioid-Induced Constipation in Advanced Illness

COLLEGEVILLE, Pa -- July 3, 2008 -- The European Commission has approved methylnaltrexone bromide (Relistor) subcutaneous for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care when response to usual laxative therapy has not been sufficient.

The use of methylnaltrexone bromide beyond 4 months has not been studied. Methylnaltrexone bromide is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. The most common adverse reactions reported in clinical trials were abdominal pain, flatulence, and nausea.

SOURCE: Progenics

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities